creatine/infarction

FIELD OF THE INVENTION The present invention relates to a new method of use for creatine compounds such as creatine kinase inhibitors and, more particularly, cyclocreatine, to block intracellular signals of the thrombin receptor Protease Activated Receptor-1, to thereby inhibit thrombin-induced

BACKGROUND OF THE INVENTION Creatine kinase (CK) occurs in animal body fluids and tissue in the form of three known isoenzymes, designated CK-BB, CK-MM and CK-MB. Each of these three isoenzymes, namely CK-BB, CK-MM, and CK-MB, differs one from the other by virtue of containing a different

BACKGROUND OF THE INVENTION Creatine kinase (CK) occurs in animal body fluids and tissue in the form of three known isoenzymes, designated CK-BB, CK-MM and CK-MB. Each of these three isoenzymes, namely CK-BB, CK-MM, and CK-MB, differs one from the other by virtue of containing a different

BACKGROUND OF THE INVENTION, AND ITS UTILITY This invention relates to the detection and quantification of serum enzymes in living organisms. The term, serum enzyme, as used herein is meant to include those enzymes occurring normally in the serum, but whose concentration will depend upon or be

FIELD OF THE INVENTION This invention relates to a method for inhibiting apoptosis in ischemic-reperfused myocardium. More specifically this invention relates to a method for using heparin or noncoagulant heparin in the prevention of apoptosis. BACKGROUND OF THE INVENTION Cells die by one of either

FIELD OF THE INVENTION The present invention concerns methods of predicting clinical outcomes such as likelihood of mortality or death, new congestive heart failure, new pulmonary congestion or the like in a patient that has received reperfusion therapy such as thrombolytic therapy. BACKGROUND OF

CROSS-REFERENCES TO RELATED APPLICATIONS This application is a national phase entry under 35 U.S.C. .sctn.371 of International Application No. PCT/CN2014/080938, filed on Jun. 27, 2014, which claims the priority of Chinese patent application Serial No. 201310572068.2 filed with the State

FIELD OF THE INVENTION The present invention relates to methods of determining if reperfusion has occurred after thrombolytic therapy during a myocardial infarction. BACKGROUND OF THE INVENTION Early and sustained coronary artery patency after thrombolytic therapy has been implicated as one of the

FIELD OF THE INVENTION The present invention relates to methods of determining if reperfusion has occurred after thrombolytic therapy during a myocardial infarction. BACKGROUND OF THE INVENTION Early and sustained coronary artery patency after thrombolytic therapy has been implicated as one of the

BACKGROUND OF THE INVENTION This invention relates to the detection and quantification of serum enzymes in living organisms. The term, serum enzyme, as used herein is meant to include those enzymes occurring normally in the serum, but whose concentration will depend upon or be affected by some